Acadia Pharmaceuticals
ACAD
263 hedge funds and large institutions have $3.56B invested in Acadia Pharmaceuticals in 2022 Q1 according to their latest regulatory filings, with 47 funds opening new positions, 80 increasing their positions, 84 reducing their positions, and 26 closing their positions.
105% more call options, than puts
Call options by funds: $35.6M | Put options by funds: $17.3M
100% more funds holding in top 10
Funds holding in top 10: 3 → 6 (+3)
81% more first-time investments, than exits
New positions opened: 47 | Existing positions closed: 26
6% more funds holding
Funds holding: 247 → 263 (+16)
3% more capital invested
Capital invested by funds: $3.46B → $3.56B (+$105M)
0.96% less ownership
Funds ownership: 92.19% → 91.23% (-0.96%)
5% less repeat investments, than reductions
Existing positions increased: 80 | Existing positions reduced: 84
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EC
EcoR1 Capital
San Francisco,
California
|
+$70.9M |
| 2 |
BC
Boxer Capital
San Diego,
California
|
+$26.1M |
| 3 |
FFM
Fairmount Funds Management
West Conshohocken,
Pennsylvania
|
+$17.9M |
| 4 |
TP
Thunderbird Partners
London,
United Kingdom
|
+$16.8M |
| 5 |
Marshall Wace
London,
United Kingdom
|
+$12.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$109M |
| 2 |
PA
Perceptive Advisors
New York
|
-$31.4M |
| 3 |
First Trust Advisors
Wheaton,
Illinois
|
-$24.7M |
| 4 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$20.7M |
| 5 |
N
Natixis
Paris,
France
|
-$13.5M |
ACAD Hedge Fund Activity: Q1 2022 in Review
263 of the 6,360 institutional investors tracked by Wall St. Rank reported a position in Acadia Pharmaceuticals (ACAD) for Q1 2022, worth a combined $3.56B — up 3% from $3.46B a quarter earlier.
Buyers outnumbered sellers: 47 funds opened new ACAD positions and 26 closed out — a net gain of 21 holders — while 80 added to existing stakes and 84 trimmed.
The largest buyer was EcoR1 Capital, adding an estimated $70.9M. The largest seller was T. Rowe Price Associates, cutting an estimated $109M.
- 263 institutional investors held Acadia Pharmaceuticals (ACAD) as of Q1 2022, up from 247 in Q4 2021.
- Funds reported $3.56B of Acadia Pharmaceuticals stock for Q1 2022, up 3% quarter-over-quarter.
- 47 funds opened new Acadia Pharmaceuticals positions in Q1 2022 and 26 closed out, a net change of +21 holders.
- The largest Acadia Pharmaceuticals buyer in Q1 2022 was EcoR1 Capital, an estimated $70.9M added.
- The largest Acadia Pharmaceuticals seller in Q1 2022 was T. Rowe Price Associates, an estimated $109M sold.
Based on aggregated 13F filings for Q1 2022.